August 10, 2009
(Date of earliest event reported)
LABORATORY CORPORATION
OF
AMERICA HOLDINGS
DELAWARE | 1-11353 | 13-3757370 | ||
(State or other jurisdiction of Incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA |
27215 | 336-229-1127 | ||
(Address of principal executive offices) | (Zip Code) |
(Registrant's telephone number including area code) |
ITEM 7.01. Regulation FD Disclosure
On August 10, 2009, Laboratory Corporation of America® Holdings (NYSE: LH) announced that its Board of Directors has authorized a new stock repurchase program under which LabCorp may purchase up to an aggregate of $250 million of its Common Stock from time-to-time.
Exhibits
99.1 Press Release dated August 10, 2009
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Laboratory Corporation of America Holdings (Registrant) |
||||
Date: August 10, 2009 | By: | /s/F. Samuel Eberts III | ||
F. Samuel Eberts III, Chief Legal Officer and Secretary |
||||
Exhibit 99.1
|
FOR IMMEDIATE RELEASE |
Laboratory Corporation of America |
Investor/Media Contact: |
358 South Main Street |
Bill Bonello (336) 436-7732 |
Burlington, NC 27215 |
Company Information: www.labcorp.com |
Telephone: (336) 584-5171 |
LabCorp Announces $250 Million Stock Repurchase Program
Burlington, NC, August 10, 2009 - Laboratory Corporation of America® Holdings (NYSE: LH) today announced that its Board of Directors has authorized a new stock repurchase program under which LabCorp may purchase up to an aggregate of $250 million of its Common Stock from time-to-time. LabCorp purchased a total of $500 million of its Common Stock under its previously announced and completed stock repurchase program, $95.2 million of which was completed since the end of the second quarter of 2009.
Any purchases under LabCorps stock repurchase program may be made from time-to-time in the open market or in privately negotiated transactions and may be initiated and discontinued at any time.
About LabCorp®
Laboratory Corporation of America® Holdings, a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $4.5 billion in 2008, over 28,000 employees worldwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, National Genetics Institute, Inc., ViroMed Laboratories, Inc., The Center for Esoteric Testing, Litholink Corporation, DIANON Systems, Inc., US LABS, and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp conducts clinical trial testing through its Esoterix Clinical Trials Services division. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about our organization, visit our Web site at: www.labcorp.com.
This press release contains forward-looking statements. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payors. Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect LabCorps financial results is included in the Companys Form 10-K for the year ended December 31, 2008, and subsequent SEC filings.
###